Cingulate

Cingulate CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Cingulate (CING) as of Nov 11, 2026 is -0.94 %. In the previous year, CapEx to Operating Cash Flow Ratio was -1.15 % — a change of -18.09% (higher).

CapEx/OCF

-0.94 %

YoY

-18.09%

Last updated:

CapEx to Operating Cash Flow Ratio of Cingulate is 2025 -0.94 % . CapEx to Operating Cash Flow Ratio of Cingulate was 2024 -1.15 % . It decreases by -18.09% higher compared to the previous year.

The Cingulate CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2019
-10.66 USD
Jan 1, 2020
-5.90 USD
Jan 1, 2021
-7.81 USD
Jan 1, 2022
-0.97 USD
Jan 1, 2023
-1.49 USD
Jan 1, 2024
-1.15 USD
Jan 1, 2025
-0.94 USD
The Cingulate CapEx/OCF history
YEARCapEx/OCFYoY
-0.94 %-18.09%
-1.15 %-22.99%
-1.49 %+54.31%
-0.97 %-87.63%
-7.81 %+32.28%
-5.90 %-44.60%
-10.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

CapEx to Operating Cash Flow Ratio of Cingulate is -0.94 % in 2025.

CapEx to Operating Cash Flow Ratio of Cingulate changed from -1.15 % to -0.94 %, representing a -18.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Cingulate since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Cingulate with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cingulate

All Key Metrics — Cingulate